Related references
Note: Only part of the references are listed.Histone deacetylase 3 as a novel therapeutic target in multiple myeloma
J. Minami et al.
LEUKEMIA (2014)
Carfilzomib: A Second-Generation Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
Jennifer L. Thompson
ANNALS OF PHARMACOTHERAPY (2013)
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
Paul G. Richardson et al.
BLOOD (2013)
Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma
Robert Z. Orlowski
CANCER CELL (2013)
Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma
Chungyee Leung-Hagesteijn et al.
CANCER CELL (2013)
Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma
Jesus F. San-Miguel et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): A joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network
Daryl Tan et al.
LEUKEMIA RESEARCH (2013)
Transcriptional Repression of Bim by a Novel YY1-RelA Complex Is Essential for the Survival and Growth of Multiple Myeloma
Veena Potluri et al.
PLOS ONE (2013)
BCR-ABL1 expression in multiple myeloma cells: A case of mistaken identity?
Roderick A. F. MacLeod et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Reply to MacLeod et al.: Multiple myeloma plasma cells have chameleon characteristics
Susanne B. Breitkopf et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma
Maria Teresa Di Martino et al.
ONCOTARGET (2013)
Proteasome inhibitors in multiple myeloma: 10 years later
Philippe Moreau et al.
BLOOD (2012)
Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival
Stella M. Ranuncolo et al.
BLOOD (2012)
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
Loredana Santo et al.
BLOOD (2012)
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma
Deborah J. Kuhn et al.
BLOOD (2012)
NF-κB and chromatin: ten years on the path from basic mechanisms to candidate drugs
Gioacchino Natoli
IMMUNOLOGICAL REVIEWS (2012)
Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies
Kian-Huat Lim et al.
IMMUNOLOGICAL REVIEWS (2012)
Dimer-specific regulatory mechanisms within the NF-κB family of transcription factors
Stephen T. Smale
IMMUNOLOGICAL REVIEWS (2012)
Molecular pathogenesis of multiple myeloma and its premalignant precursor
W. Michael Kuehl et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma
Jing-jing Huang et al.
MEDICAL ONCOLOGY (2012)
Detection of a rare BCR-ABL tyrosine kinase fusion protein in H929 multiple myeloma cells using immunoprecipitation (IP)-tandem mass spectrometry (MS/MS)
Susanne B. Breitkopf et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Transcription Factor NF-κB Inhibitors as Single Therapeutic Agents or in Combination with Classical Chemotherapeutic Agents for the Treatment of Hematologic Malignancies
Ota Fuchs
Current Molecular Pharmacology (2012)
Glycogen synthase kinase-3β is a crucial mediator of signal-induced RelB degradation
M. Neumann et al.
ONCOGENE (2011)
Classical and/or alternative NF-κB pathway activation in multiple myeloma
Yulia N. Demchenko et al.
BLOOD (2010)
Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma
Sundar Jagannath et al.
LEUKEMIA RESEARCH (2010)
Oncogenic Activation of NF-kappa B
Louis M. Staudt
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
Regulation and Function of NF-kappa B Transcription Factors in the Immune System
Sivakumar Vallabhapurapu et al.
ANNUAL REVIEW OF IMMUNOLOGY (2009)
Biologic sequelae of IκB kinase (IKK) inhibition in multiple myeloma: therapeutic implications
Teru Hideshima et al.
BLOOD (2009)
MicroRNA-221 Targets Bmf in Hepatocellular Carcinoma and Correlates with Tumor Multifocality
Laura Gramantieri et al.
CLINICAL CANCER RESEARCH (2009)
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
R. Fonseca et al.
LEUKEMIA (2009)
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenstroms Macroglobulinemia
Jacob P. Laubach et al.
LEUKEMIA & LYMPHOMA (2009)
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance
William Matsui et al.
CANCER RESEARCH (2008)
NF-κB and cancer -: identifying targets and mechanisms
Willscott E. Naugler et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2008)
Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-κB signaling
Sivakumar Vallabhapurapu et al.
NATURE IMMUNOLOGY (2008)
Noncanonical NF-kappa B activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK
Brian J. Zarnegar et al.
NATURE IMMUNOLOGY (2008)
Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper
Mette Munk Jensen et al.
BMC MEDICAL IMAGING (2008)
Genetic events in the pathogenesis of multiple myeloma
W. J. Chng et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2007)
Epigenetic targets in hematological malignancies: Combination therapies with HDACis and demethylating agents
Mark Bishton et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma
Jonathan J. Keats et al.
CANCER CELL (2007)
Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma
Christina M. Annunziata et al.
CANCER CELL (2007)
The cancer stem cell hypothesis: a work in progress
Brenton Thomas Tan et al.
LABORATORY INVESTIGATION (2006)
Histone deacetylase (HDAC) inhibitor LBH589 increases duration of γ-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer
Ling Geng et al.
CANCER RESEARCH (2006)
Introduction to NF-κB:: players, pathways, perspectives
T. D. Gilmore
ONCOGENE (2006)
The molecular classification of multiple myeloma
Fenghuang Zhan et al.
BLOOD (2006)
NF-κB and cancer:: Mechanisms and targets
Michael Karin
MOLECULAR CARCINOGENESIS (2006)
Nuclear factor-κB in cancer development and progression
Michael Karin
NATURE (2006)
A selective small molecule I kappa B kinase beta inhibitor blocks nuclear factor kappa B- mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells
Danyi Wen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Active repression of antiapoptotic gene expression by ReIA(p65) NF-κB
KJ Campbell et al.
MOLECULAR CELL (2004)
Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis
RB Vega et al.
CELL (2004)
p53 Represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-κB subunit with histone deacetylase 1
S Rocha et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Differential requirement for Rel/nuclear factor κB family members in natural killer T cell development
V Sivakumar et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
RelB is required for Peyer's patch development: differential regulation of p52-RelB by lymphotoxin and TNF
ZB Yilmaz et al.
EMBO JOURNAL (2003)
NF-κB in cancer:: From innocent bystander to major culprit
M Karin et al.
NATURE REVIEWS CANCER (2002)
Signaling molecules of the NF-κB pathway shuttle constitutively between cytoplasm and nucleus
A Birbach et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Multiple myeloma: Evolving genetic events and host interactions
WM Kuehl et al.
NATURE REVIEWS CANCER (2002)
Signal-specific and phosphorylation-dependent RelB degradation:: a potential mechanism of NF-κB control
R Marienfeld et al.
ONCOGENE (2001)
Activation by IKKα of a second, evolutionary conserved, NF-κB signaling pathway
U Senftleben et al.
SCIENCE (2001)
Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer
SB Baylin et al.
HUMAN MOLECULAR GENETICS (2001)
Share Paper
